Chan-Yen Tsai
Overview
Explore the profile of Chan-Yen Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Dana W, Shih W, et al.
Ann Hematol
. 2025 Jan;
104(1):335-345.
PMID: 39804351
Polycythemia vera (PV) is characterized by clonal hematopoietic stem or progenitor cells with constitutively active somatic mutation(s) in the Janus kinase 2 gene. Phlebotomy (Phl) and aspirin are often used...
2.
Xu X, Yan S, Yo Y, Chiang P, Tsai C, Lin L, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272910
Programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) interact to form an immune checkpoint fostering viral infection and viral oncogene-induced tumorigenesis. We generated a novel anti-human PD-1, humanized...
3.
Liu W, Feng P, Cheng C, Chou C, Lee C, Lu M, et al.
Infect Dis Ther
. 2024 May;
13(7):1575-1588.
PMID: 38771550
Introduction: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection. Methods: This is a multicenter, randomized, open-label...
4.
Qin A, Wu C, Ho M, Tsai C, Chen P
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203603
Hepatocellular carcinoma (HCC) usually recurs after curative surgical resection. Currently, no approved adjuvant therapy has been shown to reduce HCC recurrence rates. In this study, the in vivo effect of...
5.
Liu W, Hou H, Li K, Qin A, Tsai C, Sheng W
Adv Ther
. 2023 Nov;
41(2):847-856.
PMID: 38010606
Introduction: Ropeginterferon alfa-2b represents a new-generation PEGylated interferon. It is approved for the treatment of polycythemia vera and shows promising anti-SARS-CoV-2 activities. Objective: This clinical study aims to evaluate the...
6.
Lo C, Chuang W, Kuo H, Chen W, Qin A, Tsai C, et al.
J Formos Med Assoc
. 2023 Sep;
123(1):55-61.
PMID: 37666718
Aim: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. Its biweekly dosing schema has demonstrated tolerability and clinical efficacy for treating chronic hepatitis in previous clinical studies. This trial evaluates the...
7.
Chen C, Chuang W, Qin A, Zhang W, Zhu L, Zhang G, et al.
JGH Open
. 2022 Nov;
6(11):782-791.
PMID: 36406648
Background And Aim: Ropeginterferon alfa-2b is a novel mono-pegylated, extra-long-acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment...
8.
Huang Y, Qin A, Tsai C, Chen P
Viruses
. 2022 Jun;
14(6).
PMID: 35746606
Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less...
9.
Chen K, Lee K, Qin A, Luo C, Yeh Y, Zheng J, et al.
Adv Ther
. 2021 Dec;
39(2):910-922.
PMID: 34910280
Introduction: This study, for the first time to our knowledge, evaluated the efficacy of ropeginterferon alfa-2b, a long-acting pegylated interferon (IFN)-alfa, in the treatment of COVID-19. Methods: We retrospectively evaluated...
10.
Huang Y, Tsai C, Tsai C, Wang W, Zhang J, Qin A, et al.
Adv Ther
. 2021 Jul;
38(9):4756-4770.
PMID: 34328630
Introduction: Ropeginterferon alfa-2b is a novel mono-pegylated human recombinant interferon (IFN) with the addition of N-terminal proline covalently attached by a 40-kDa polyethylene (peg) moiety. The present study aimed to...